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This paper consists of four sections. First, it describes the Center for Science in the Public 
Interest (CSPI) and its Biotechnology Project. Second, it discusses the current status of 
agricultural biotechnology in the United States, future trends for the technology and some 
of the controversy that surrounds it. Third, the paper discusses the current status and 
issues surrounding “biopharming,” a major topic at this conference. The paper concludes 
with a discussion of what is needed for broader acceptance of agricultural biotechnology, 
not just in the United States but also abroad.
the Center for Science in the Public Interest
CSPI is a nonprofit consumer-advocacy organization that has focused on improving the 
safety and nutritional quality of our food supply. It seeks to promote health through 
educating the public about nutrition and alcohol; it represents citizens’ interests before 
legislative, regulatory, and judicial bodies; and it works to ensure that advances in science 
are used for the public good. Its primary focus is on the United States, although it does 
have a satellite office in Canada. International activities involve food-safety and labeling 
issues, such as the Codex	Alimentarius and the trans-Atlantic Consumer Dialogue.
CSPI is primarily supported by the almost 900,000 member-subscribers to its Nutrition	
Action	Healthletter.	CSPI receives no funding from industry or the federal government; 
some funding comes from independent philanthropic foundations.
The	Biotechnology	Project
In 00, CSPI began an advocacy project on agricultural biotechnology, the goals of 
which include to accurately identify risks and benefits of biotechnology, to ensure that 
the US regulatory system is up to the task of preventing significant risk, and to keep the 
public informed about the facts surrounding agricultural biotechnology. 
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CSPI’s biotechnology positions are based upon current evidence about the risks and 
benefits of biotechnology, not upon an ideological viewpoint that agricultural biotechnol-
ogy is inherently good or bad. In 00, based on its review of currently available evidence, 
CSPI stated that “the genetically engineered foods that are currently on the market are 
safe” to eat and that environmental risks associated with those crops are manageable 
(CSPI, 00). Also, CSPI has stated on numerous occasions that currently engineered 
crops grown in the United States are yielding benefits to farmers and the environment 
by increasing yields and reducing the use of insecticides (CSPI, 00; Jacobson, 00a, 
00b; Jaffe, 00). CSPI publicly acknowledges these beneficial applications and wants 
to ensure that they will continue to be realized. CSPI has been disappointed that other 
crops that could provide similar environmental benefits, such as Monsanto’s NewLeaf ™ 
potato, have not been planted by farmers due to fear of a consumer backlash and a loss 
of market for the crop.
Of course, CSPI has also acknowledged that agricultural biotechnology has real risks 
that need to be assessed and addressed before products from genetically engineered (GE) 
crops are marketed. From the consumer’s point of view, the key question about biotech 
foods is “Are they safe?” (Jaffe, 00a). Thus, before a biotech food is marketed, there 
needs to be a determination that the engineered protein is not an allergen, that there is 
no toxic effect from the engineered crop, and that there is no other unintended effect 
from the genetic transformation (NrC, 000, 00; CSPI, 00). Environmental risks 
are also possible from engineered crops. There is the potential for harm to non-target 
species, or the spread of the introduced gene and its characteristics to wild relatives of the 
transformed crop, or the development of pesticide resistance in insects or weeds (NrC, 
000; CSPI, 00). Each possible environmental consequence needs to be thoroughly 
evaluated and adequately addressed before any biotech crop is released to the environ-
ment (Jaffe, 00a).
Current Status of Agricultural Biotechnology and 
Future Potential Applications
In many ways, the past 0 years have been extremely successful for the biotechnology 
industry. Several blockbuster products were marketed in the 990s, including soybeans, 
corn, cotton, and canola that are herbicide-tolerant and corn and cotton that produce 
their own insecticide that kills specific pests. Those GE crops have been widely adopted 
by farmers in the United States and, to a varying extent, in seventeen other countries 
around the globe. Over eight million farmers grew 00 million acres of GE crops in 00 
(ISAAA, 005). From 99 to 00, the global acreage of transgenic crops increased 7-
fold, from . million acres to approximately 00 million acres (ISAAA, 005). In the 
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United States, 3.5 million acres of GE corn (5% of all corn) and 3.5 million acres of 
GE soybeans (85% of all soybeans) were grown in 00 (USDA, 00).
Those herbicide-tolerant and insect-resistant crops—biotechnology’s “first genera-
tion”—have been found to be safe to humans and the environment in the United States. 
They have also provided benefits to farmers and the environment by increasing yields, 
reducing the use of insecticides or increasing farmer income. 
Although the biotechnology industry’s initial inventions have been quite successful, the 
introduction of new products with different traits has slowed considerably. In February, 
005, CSPI released a study, Withering	on	the	Vine:	Will	Agricultural	Biotech’s	Promises	
Bear	Fruit? (Jaffe, 005). That study analyzed publicly available data from federal regula-
tory agencies to determine whether the number of new commercial products has been 
increasing, decreasing or remained steady. 
The study found that sixty-two biotech crops completed the Food and Drug Admin-
istration’s (FDA) voluntary consultation process between 995 and 00 (Figure ). In 
the first 5 years (995 through 999), forty-seven of those crops (an average of 9. per 
year) completed the regulatory process, whereas only fifteen crops (an average of three 
per year) completed the process in the next five years (000 through 00). Thus, the 
number of products per year completing the regulatory process plunged by 8% between 
995–999 and 000–00. More than 75% of all biotech crops that have completed 
the FDA regulatory process did so between 995 and 999. 
Figure . Genetically engineered crops completing FDA’s 
voluntary consultation process (FDA, 005).
Similarly, publicly available data about the granting of petitions for non-regulated 
status by the Animal and Plant Health Inspections Service (APHIS) of the United Stated 
Department of Agriculture (USDA) show a decreasing trend starting in 000. From 99 
through 00 ( years), APHIS deregulated sixty-two biotech crops so that they could 
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be grown commercially without APHIS oversight. Forty-nine of those approvals occurred 
between 99 and 999 (an average of 8. per year) while only thirteen of those approvals 
occurred between 000 and 00 (an average of . per year) (Figure ). Thus, APHIS 
approved almost four times as many crops from 99 through 999 than from 000 
through 00. Clearly, the pipeline for new biotech crops has shrunk considerably, and 
few new products have become available for commercialization in recent years.
The CSPI study also found that the GE crops that completed the regulatory process 
starting in 000 tended to be variations of existing products with established and proven 
genes, rather than innovative applications of the technology. For example, of the fifteen 
consultations at FDA between 000 and 00, five involved Monsanto’s placing in 
corn, wheat, creeping bent grass, canola, and sugar beet the same gene for resistance to 
the herbicide glufosinate ammonium (roundup®) that was previously engineered into 
soybean and cotton and reviewed by FDA in 995. Three applications of the fifteen 
involved engineering corn, rice, and cotton with a different gene (for phosphinothricin 
acetyltransferase) conferring herbicide tolerance that several companies had previously 
engineered into other crops that completed the FDA consultation process in the 990s. 
The remaining seven GE products involved engineering corn and cotton with various 
cry genes from Bacillus	thuringiensis	that confer insect resistance.	Although some of those 
applications could be considered “new” because they used cry genes not previously ap-
proved to address different plant pests, the Bt technology had been reviewed by FDA in 
consultations that go as far back as 995. Therefore, in the past 5 years, the industry has 
not marketed a single new agronomic, nutritional, or other trait.
Figure . Genetically engineered crop petitions approved by USDA for 
non-regulated status (APHIS, 005a)
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The CSPI study also looked at length of time to complete the regulatory reviews of 
engineered crops at FDA and APHIS, which it concluded has significantly increased 
between 000 and 00. For the sixty-two voluntary consultation reviews conducted by 
FDA, the submissions from 995 through 999 averaged . months for completion 
whereas the submissions from 000 to 00 averaged 3.9 months (Jaffe, 005). Similarly, 
at APHIS granting a petition for non-regulated status took an average completion time 
of 5.9 months from 99 to 999, but an average of 3. months from 000 to 00 
(Jaffe, 005). Thus, it took the federal government twice as long to review biotech crops 
from 000 to 00 than it did in the 990s, yet those products had no apparent novel 
considerations that might justify the longer reviews. 
While the pipeline has slowed, international controversy over current engineered crops 
has continued. Whereas most governments and many distinguished scientists have found 
that those crops are safe, some people continue to be concerned with their safety to hu-
mans and/or the environment. Similarly, many opponents of genetic engineering do not 
believe that the current crops have any benefits, not just to consumers, but to farmers or 
the environment. Also, people throughout the world have called for the labeling of those 
crops and products from them, and many governments have imposed such labeling and 
traceability requirements (USDA, 005).
The	controversy	over	genetic	engineering	will	only	increase	with	
the	next	generation	of	products.
The controversy over genetic engineering will only increase with the next generation 
of products. The biotechnology industry and university researchers in the United States 
and abroad have been inserting a wide range of engineered traits into many different 
organisms. While research on drought or salt tolerance may reduce the controversy 
over genetic engineering if they benefit small-scale farmers in developing countries, 
GE wheat and rice will likely increase the international controversy. Those applications 
are particularly controversial because those crops are grown primarily for human food 
needs, whereas the currently grown engineered corn and soybeans are primarily used for 
animal feed (Foreman, 005). Similarly, applications of genetic engineering to animals 
to make faster growing salmon or improved cattle will be extremely controversial as they 
raise both safety and ethical issues (NrC, 00a; Foreman, 005). Finally, engineering 
plants to make pharmaceuticals (“biopharming”) or industrial compounds is particularly 
worrisome when food crops are employed because no one wants to eat corn flakes with 
a pharmaceutical in them. 
It is clear that those future applications of biotechnology may result in more contro-
versy than the current crops. Already, the possibility that the next generation of products 
might come to market has sparked an increase in state legislation to hinder or prevent 
commercialization of those products. In the 003–00 legislative session, the Northern 
Plains states (Montana, North Dakota, and South Dakota) introduced legislation to 
curb the introduction of GE wheat, while Michigan, California and Alaska introduced 
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legislation to put limits on transgenic fish (Pew, 005). In addition, Hawaii and texas 
have introduced legislation limiting production of pharmaceuticals using food crops (Pew, 
005). Although the 005–00 legislative session has only just started, both Hawaii and 
Oregon have already introduced legislation on pharma crops. Thus, it is more important 
than ever to do whatever possible to ensure acceptance of those crops when they reach 
the marketplace.
Biopharming
Introduction
In the last couple of years, the biotechnology industry has engaged in genetically engineer-
ing plants to produce pharmaceuticals, industrial compounds, and other novel proteins 
(“biopharming” or “pharma crops”) (Jaffe, 00b). Products that manufacturers hope 
to market commercially include insulin from safflower, human serum albumin (used as 
blood volume replacement during shock, serious burns, and surgery) from corn, hepatitis 
B vaccine from tobacco, cholera and Norwalk virus vaccines in potatoes, and lactoferrin 
(a human protein that protects against infections) in rice.
For the 00 growing season, USDA, which regulates the planting of pharma crops, 
received twenty applications to grow them in ten states. (Jaffe, 00b). For the 005 
growing season, they received eighteen applications to grow them in seven states (APHIS, 
005a). Those applications involve the engineering of six different crops—corn, tobacco, 
safflower, barley, rice, and indian mustard—with corn, tobacco and rice constituting the 
majority of the applications (Figure 3).
Figure 3. Biopharming permit applications for 00 and 005, by crop (APHIS, 005b).
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Although those applications of the technology have the potential to provide consumer 
benefits, if misused they could harm consumers or the environment. In fact, many sci-
entists and other stakeholders believe that the risks from pharma crops are significantly 
greater than those from engineered crops grown for food purposes. The National research 
Council stated the following in its report entitled Environmental	Effects	of	Transgenic	Plants 
about the potential risks of biopharming (NrC, 00b):
Some	 of	 the	 coming	 applications	 of	 biotechnology	may	 involve	 the	 issuing	 of	
plants	to	produce	pharmaceutical	products,	biologics,	fuels,	and	other	substances	
not	intended	for	human	food	use.	The	introduction	of	such	transgenes	poses	the	
potential	for	environmentally	associated	risks	of	a	wholly different order	than	
those	associated	with	existing	 transgenic	crops.	 If	 such	a	 transgene	moves	 into	
food	crops,	either	through	pollen	transfer	or	physical	contamination,	there	could	
be	serious human safety risk.	If	such	a	transgene	moves	into	a	wild	relative,	
there	could	be	widespread	environmental	dissemination	of	the	pharmaceutical	
substance	or	other	nonfood	substances	that	could have impacts on wildlife as 
well as microbial populations.	(emphasis added)
While biopharming raises both environmental and food-safety issues, the controversy 
surrounding those crops has centered on the concern that they might inadvertently en-
ter the food supply, causing either recalls of food products or rejection by international 
trading partners. That concern has caused industry stakeholders who normally support 
agricultural biotechnology to become advocates either against biopharming or for more 
stringent regulations. The Food Products Association has stated that it “has grave concerns 
about the use of bioengineered food and feed plants to produce non-food products” and 
that (FPA, 003):
…given	a	voice	during	the	early	development	of	this	promising	technology,	[FPA]	
would	not	have	supported	the	use	of	food	crops	for	the	production	of	plant	made	
pharmaceuticals.
Similarly, the Grocery Manufacturers of America stated (GMA, 003b):
The	current	US	regulatory	 framework	does	not	 inspire	 confidence	among	our	
collective	members	that	these	drug	and	chemical	crops	will	remain	isolated	and	
confined	and	not	contaminate	the	food	supply.
In fact, it is as likely that an industry stakeholder will object to the planting of a pharma 
crop as one generally opposed to agricultural biotechnology. When the biopharming 
company Ventria Bioscience attempted to plant rice engineered to produce a pharmaceu-
tical, Anheuser-Busch objected and was able to use its market power to alter where and 
under what conditions that rice would be grown (Bennett, 005). Similarly, Agragen’s 
announced intention to grow flax engineered to produce albumin in North Dakota, re-
sulted in industry stakeholders such as AmeriFlax expressing opposition out of fear that, 
even without a contamination incident, their international markets for conventional 
flax will be jeopardized (Associated Press, 005). Thus, it is clear that biopharming using 
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food crops is radically changing the debate surrounding agricultural biotechnology so 
that stakeholders who either supported or would support certain applications of genetic 
engineering, don’t support biopharming in food crops.
Regulation	of	Biopharming	and	the	USDA
A rigorous and robust regulatory system for ensuring that biopharm crops are safe for 
humans and the environment would do the following:1
• Allow the planting of pharma crops only if the government issues a permit. The 
regulatory system should put in place mandatory permitting requirements that 
must be complied with before the growing of any pharma crop. The permitting 
process should be transparent and allow public participation before the issuance 
of the permit.
• Issue a permit only after a thorough environmental assessment of the potential 
risks from growing the pharma crop. Before a permit is issued, the government 
should conduct a thorough environmental assessment of the potential effects of 
growing the pharma crop, including the effects from flow of the introduced gene 
and the effects of the transgenic protein on species other than humans. 
• Issue permits that require strict biological and physical confinement measures. 
All permits should contain enforceable conditions requiring state-of-the-art 
confinement procedures. Those mandatory permit conditions should include 
isolation distances, geographic restrictions (such as not growing GE corn in 
parts of the country where commodity corn is grown), physical barriers (such as 
fences or greenhouses), the use of distinguishable varieties of the crop, biological 
confinement (such as male sterility), and so forth. The permit should also require 
extensive segregation and identity-preservation procedures that ensure that none 
of the harvested materials can commingle with crops destined for human or 
animal consumption. When using a food crop, the permit should have several 
redundant levels of confinement, even at the field-trial level.
• Require regular inspections of the pharmaceutical-producing crop by the regula-
tory agencies. As part of its regulation of pharma crops, both USDA and FDA 
should conduct regular, unannounced inspections of all facilities involved in the 
production of the pharmaceutical, from the laboratory to the farm to the manu-
facturing plant. Some of those inspections should occur after the crops have been 
harvested to prevent volunteer plants in future seasons. In addition, USDA and 
FDA should inspect neighboring fields and crops to confirm that containment 
has been achieved.
• Require that if a pharmaceutical is produced in a food crop, there should be a 
mandatory pre-market food-safety approval process by FDA’s Center for Food 
1The remainder of this article focuses on federal regulation of biopharming. It does not discuss state or local 
regulations, which could play a major role in overseeing the risks associated with pharma crops.
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Safety and Applied Nutrition. Although confinement measures need to be strictly 
adhered to, they will never result in 00% containment over the long term. Thus, 
before any pharmaceutical is grown commercially in a food crop, FDA should 
conduct a thorough food-safety analysis to ensure that human exposure to the 
transgenic crop in the food supply would not result in any health risks. If addi-
tional legal authority is needed to implement this requirement, FDA and USDA 
should seek it from Congress.
Such a regulatory system would be able to protect human health and the environment, 
provide consumers confidence that their concerns are being adequately addressed, and 
lead to general acceptance of biopharming applications that are found safe. Unfortu-
nately, the regulatory system for biopharming in the United States does not meet those 
minimum requirements.
The USDA regulates biopharming using its biotechnology regulations established under 
the authority of the Plant Pest Act (7 CFr 30). Under those regulations, a permit must 
be issued before any biopharm plant can be released into the environment. Applicants 
submit an application and USDA conducts some risk analysis of the proposed planting. 
USDA then issues a permit with specific confinement conditions and conducts inspec-
tions during the release to verify compliance.
Unfortunately, the USDA permitting system for biopharming is not as rigorous, trans-
parent, or protective as is needed to ensure safety for humans and the environment. First, 
it lacks transparency and the ability for the public to participate in many of the regulatory 
decisions. The non-confidential portion of the applications for biopharming permits are 
not made available to the public nor is any information about the general location or 
size of the release. Also, when the permit is issued, it is not made available to the public. 
In addition, the public is not informed about how many inspections are to be made at 
a particular site or the results of those inspections. Finally, there is no opportunity for 
public comment before the issuance of many biopharming permits. The public is given 
an opportunity to comment on a proposed permit only if an Environmental Impact 
Statement or Environmental Assessment is performed under the National Environmental 
Policy Act, which occurs in only a small minority of biopharming permits. In contrast, for 
every other engineered crop, before a petition for non-regulated status is granted (which 
is generally the last step before commercialization), the public is given the opportunity 
to comment on the regulatory decision.
The	USDA	permitting	system	for	biopharming	is	not	as	rigorous,	
transparent,	or	protective	as	is	needed	to	ensure	safety	for	humans	
and	the	environment.
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Due to the lack of transparency in USDA’s regulation of biopharming, it is difficult to 
assess whether or not their permitting system adequately protects the environment. The 
National research Council reviewed some of the environmental assessments for transgenic 
food crops and found that they were not thorough and did not address broad ecological 
issues (NrC, 00b). Some of the documents that have been released by USDA on their 
assessment of environmental issues surrounding biopharming have been extensive while 
others were extremely cursory. Thus, it is fair to state that USDA’s environmental assess-
ments for biopharming do not always thoroughly analyze gene flow, effects on non-target 
species, or any broad ecological effects of the transgenic plant. 
Based on the documents released to the public about the permit conditions imposed on 
biopharming (USDA guidance as well as proposed supplemental conditions), the USDA 
does not require strict biological and physical confinement measures using state-of-the-art 
technologies. USDA primarily employs geographic and temporal separations and has not 
required biological confinement measures (e.g. male sterility or chloroplast transformation) 
nor geographic restrictions (such as not growing pharma corn in corn-belt states). Only 
by using all available confinement measures in a redundant fashion can both human and 
environmental health be safeguarded from biopharm crops.
Finally, although USDA has the legal authority to address agricultural and environ-
mental issues surrounding biopharming, they have no Congressional mandate to address 
food-safety concerns. Under the Plant Protection Act, which USDA uses to promulgate 
its biotechnology regulations, there is no authority to safeguard the food supply. For this 
reason, USDA’s permitting process does not involve any food-safety assessment of a pharma 
crop before it is released into the environment. USDA’s assessment process does not de-
termine whether the gene product will be harmful to humans if it enters the food supply. 
At the same time, FDA does not conduct any food-safety assessments of pharma crops. 
Thus, there is an extremely large gap in the federal government’s regulation of biopharming 
where no agency assesses and addresses the food-safety risks of pharma crops.
The	Need	for	FDA	to	Regulate	Biopharming	and	Safeguard	the	Food	Supply	
The Federal Food Drug and Cosmetic Act regulates anything that is intended to be used as 
food or feed. However, a pharmaceutical corn plant or one producing avidin, for example, 
is not intended by the developer to be used as food or feed. Thus, those products are 
neither food additives, nor would they be subject to FDA’s voluntary notification process 
(or FDA’s proposed mandatory notification rule). FDA has limited authority over those 
products unless they show up in food. At that stage, FDA could consider foods containing 
the pharmaceutical compound (or industrial chemical) adulterated, and remove them 
from the market. The burden would be on FDA, however, to prove adulteration.
The current system is not the best way to ensure a safe food supply in view of the fact 
that contamination by pharma crops is inevitable. A possible solution to this problem 
would be for Congress to require a mandatory FDA approval process for all GE crops, both 
those intended for food use and pharma crops not intended for the food supply. Under 
that approval system, no GE food crop could be commercialized without a food-safety 
approval by FDA. For pharma crops to be commercialized, FDA would either need to 
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approve the crop as safe to eat or set a safe tolerance for the non-food substance. Then, 
if that GE crop entered the food supply, eating the engineered substance would be safe 
as long it was below the tolerance level; consumers would have no need to fear that they 
are eating unsafe food. In addition, the rigor of the food-safety assessment conducted by 
FDA should be proportionate to the physical and biological confinement of the crop. If 
the pharmaceutical crop is grown at a location far from other like plants, only a limited 
food-safety assessment might be required because the likelihood of contamination would 
be extremely small. If pharmaceutical corn is grown in Iowa, however, then a complete 
food-safety analysis might be warranted. 
Providing FDA with mandatory authority to review the safety of pharma crops before 
they are released into the environment is not a far-fetched idea. As far back as 00, a 
group of industry representatives at the Grain Quality Workshop concluded the follow-
ing (Maier, 00):
[We]	urge	the	FDA	that	when	future	commercialization	approvals	of	genetically	
modified	grains	and	oilseeds	for	non-food	and	feed	purposes	are	considered,	these	
approvals	also	meet	food	safety	requirements	because	inadvertent	traces	of	these	
genetically	modified	grains	and	oilseeds	will	be	detected	in	food	and	feed.
The Grocery Manufacturers of America (003a) also stated that pharma crops should 
not be grown:
…unless	FDA	has	concluded	that	any	release	of	the	nonfood	product	into	the	food	
supply	will	be	safe	and	that	it	will	have	no	adverse	effect	on	human	health.
Other countries have also included food-safety assessments for biopharming. In 
Canada, if a food or feed crop is used for biopharming (Canadian Food Inspection 
Agency, 000):
…the	developer	must	submit	exposure	and	hazard	data	for	human	and	livestock	
health	effects	assessment	[by	Health	Canada].	
Finally, in the 07th Congress, Senator richard Durbin from Illinois introduced the 
Genetically Engineered Foods Act (S. 5). That bill would require all GE food crops to 
have a mandatory premarket approval before commercialization, including pharma crops. 
Therefore, many stakeholders agree that there are significant risks to the food supply from 
pharma crops and that a regulatory agency, such as FDA, needs to play a mandatory role 
in ensuring that those crops do not cause harm to humans. 
Providing	FDA	with	mandatory	authority	to	review	the	safety	of	
pharma	crops	before	they	are	released	into	the	environment	is	not	
a	far-fetched	idea.
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the road Forward for Acceptance of Agricultural Biotechnology
With the current state of affairs and the many controversial new applications on the 
horizon, agricultural biotechnology is unlikely to obtain broader societal acceptance in 
the near future. This will be particularly true for applications of the technology such as 
biopharming.
to create the proper environment for greater acceptance of agricultural biotechnology 
products, there should be the following:
• a strong, but not stifling, regulatory system that manages the potential risks of 
products using scientific risk assessments and state of the art technology;
• a regulatory system that is transparent and participatory;
• independent risk-assessment research that informs the public and regulators about 
the potential risks of particular applications and how to manage those risks;
• applications of the technology that provide direct benefits to consumers, both in 
developed and developing countries;
• broader access to the technology through the free licensing of intellectual-prop-
erty rights to public-sector and developing-country researchers making products 
for the public good;
• involvement of the public early on in the development of products so that contro-
versial and/or risky applications can be avoided.
Agricultural biotechnology is one of the many tools available to move agriculture 
forward in the twenty-first century. It can provide beneficial products, including pharma-
ceuticals. to properly utilize biotechnology, however, the regulatory system must ensure 
that products are safe for humans and the environment. That system must be transparent 
and participatory if it is to engender trust among consumers. Only then will there be an 
environment in which consumers will embrace safe applications of biotechnology.
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